{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:09:36Z","timestamp":1787785776739,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.intimp.2017.10.008","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T14:30:44Z","timestamp":1510237844000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM\/CD3-bispecific BiTE antibody MT110 efficacy against IDO1hibreast cancer via enhancing immune cells activity"],"prefix":"10.1016","volume":"54","author":[{"given":"Ri","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2017.10.008_bb0005","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.2741\/2911","article-title":"EpCAM expression in normal, non-pathological tissues","volume":"13","author":"Schmelzer","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.intimp.2017.10.008_bb0010","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s001099900038","article-title":"The biology of the 17\u20131A antigen (Ep-CAM)","volume":"77","author":"Balzar","year":"1999","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.intimp.2017.10.008_bb0015","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2017.10.008_bb0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bjc.6603494","article-title":"EpCAM (CD326) finding its role in cancer","volume":"96","author":"Baeuerle","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2017.10.008_bb0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.bjc.6602924","article-title":"Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers","volume":"94","author":"Went","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2017.10.008_bb0030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Ben-Porath","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.intimp.2017.10.008_bb0035","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/S0022-5347(05)68341-3","article-title":"Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia","volume":"162","author":"Poczatek","year":"1999","journal-title":"J. Urol."},{"key":"10.1016\/j.intimp.2017.10.008_bb0040","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/sj.bjc.6600741","article-title":"Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival","volume":"88","author":"Spizzo","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2017.10.008_bb0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","article-title":"Frequent EpCam protein expression in human carcinomas","volume":"35","author":"Went","year":"2004","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.intimp.2017.10.008_bb0050","first-page":"4105","article-title":"The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice a new model to study carcinoma-directed immunotherapy","volume":"61","author":"McLaughlin","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2017.10.008_bb0055","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/carcin\/bgq187","article-title":"EpCAM in carcinogenesis: the good, the bad or the ugly","volume":"31","author":"van der Gun","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.intimp.2017.10.008_bb0060","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/0008-5472.CAN-04-0754","article-title":"EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy","volume":"64","author":"Osta","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2017.10.008_bb0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2011.04.002","article-title":"Epithelial cell adhesion molecule expression (CD326) in cancer: a short review","volume":"38","author":"Patriarca","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2017.10.008_bb0070","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(00)03312-2","article-title":"Ep-CAM overexpression in breast cancer as a predictor of survival","volume":"356","author":"Gastl","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2017.10.008_bb0075","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cbpa.2013.03.029","article-title":"Targeting T cells to tumor cells using bispecific antibodies","volume":"17","author":"Frankel","year":"2013","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.intimp.2017.10.008_bb0080","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2017.10.008_bb0085","series-title":"MAbs","first-page":"539","article-title":"Bispecific antibodies for cancer therapy: the light at the end of the tunnel?","author":"Chames","year":"2009"},{"key":"10.1016\/j.intimp.2017.10.008_bb0090","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.intimp.2017.10.008_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-07-2182","article-title":"Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3","volume":"68","author":"Amann","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2017.10.008_bb0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2017.10.008_bb0105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/CJI.0b013e3181a1c097","article-title":"Antitumor activity of an EpCAM\/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release","volume":"32","author":"Amann","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2017.10.008_bb0110","series-title":"ASCO Annual Meeting Proceedings","first-page":"2573","article-title":"Phase I safety and pharmacology study of the EpCAM\/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer","author":"Fiedler","year":"2010"},{"key":"10.1016\/j.intimp.2017.10.008_bb0115","series-title":"ASCO Annual Meeting Proceedings","first-page":"2504","article-title":"A phase I study of EpCAM\/CD3-bispecific antibody (MT110) in patients with advanced solid tumors","author":"Fiedler","year":"2012"},{"key":"10.1016\/j.intimp.2017.10.008_bb0120","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1126\/science.1073514","article-title":"Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase","volume":"297","author":"Munn","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.intimp.2017.10.008_bb0125","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2017.10.008_bb0130","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.4049\/jimmunol.164.7.3596","article-title":"Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation","volume":"164","author":"Hwu","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2017.10.008_bb0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1535-7163.MCT-09-0628","article-title":"Hydroxyamidine inhibitors of indoleamine-2, 3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors","volume":"9","author":"Koblish","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2017.10.008_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00262-013-1393-y","article-title":"Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry","volume":"62","author":"Soliman","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2017.10.008_bb0145","first-page":"1304","article-title":"[Indoleamine 2, 3-dioxygenase activity in breast cancer patients with local recurrence or distant metastases]. Gan to kagaku ryoho","volume":"41","author":"Sakurai","year":"2014","journal-title":"Cancer Chemother."},{"key":"10.1016\/j.intimp.2017.10.008_bb0150","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1021\/jm900518f","article-title":"Discovery of potent competitive inhibitors of indoleamine 2, 3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model","volume":"52","author":"Yue","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2017.10.008_bb0155","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/0008-5472.CAN-06-2925","article-title":"Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses","volume":"67","author":"Hou","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2017.10.008_bb0160","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.4049\/jimmunol.166.12.7556","article-title":"Peripheral blood fibrocytes: differentiation pathway and migration to wound sites","volume":"166","author":"Abe","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2017.10.008_bb0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1078-0432.CCR-11-1270","article-title":"EpCAM\/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells","volume":"18","author":"Cioffi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2017.10.008_bb0170","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2017.10.008_bb0175","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1593\/neo.13168","article-title":"Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes","volume":"15","author":"Zhou","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2017.10.008_bb0180","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/S0021-9258(17)30447-7","article-title":"Indoleamine 2, 3-dioxygenase. Purification and some properties","volume":"253","author":"Shimizu","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2017.10.008_bb0185","first-page":"171","article-title":"Th1\/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens","volume":"81","author":"Surcel","year":"1994","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2017.10.008_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2017.10.008_bb0195","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1038\/sj.onc.1207610","article-title":"The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation","volume":"23","author":"M\u00fcnz","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2017.10.008_bb0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/imr.12143","article-title":"Engineering T cells for cancer: our synthetic future","volume":"257","author":"Vonderheide","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2017.10.008_bb0205","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2017.10.008_bb0210","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2017.10.008_bb0215","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12245","article-title":"Novel immunotherapies for hematologic malignancies","volume":"263","author":"Nelson","year":"2015","journal-title":"Immunol. Rev."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917303776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917303776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T22:38:21Z","timestamp":1659825501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576917303776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":43,"alternative-id":["S1567576917303776"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.10.008","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM\/CD3-bispecific BiTE antibody MT110 efficacy against IDO1hibreast cancer via enhancing immune cells activity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}